Is the efficacy of epoetin beta in anemic peritoneal dialysis patients maintained with fortnightly doses?
Peter Bárány
Correspondence Department of Renal Medicine, K56 Karolinska University, Hospital Huddinge, SE-141 86 Stockholm, Sweden
Email peter.barany@klinvet.ki.se
This article has no abstract so we have provided the first paragraph of the full text.
The optimal frequency of epoetin administration in patients with renal anemia is still debated. This study by Grzeszczak et al. provides new data on management of anemia in peritoneal dialysis patients. In an open-label, randomized, controlled multicenter study, the investigators showed that reducing the dosage frequency of subcutaneous epoetin beta to once per week in peritoneal dialysis patients previously receiving stable twice-weekly or thrice-weekly doses maintains hemoglobin levels without need for a significant dose increase. Stable hemoglobin levels were also maintained when the dosage interval was extended from 1 week to 2 weeks, but a 13% increase in epoetin dose was necessary in this group.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
